Buy Mephedrone (4-MMC)

Description

Mephedrone (4-MMC) also known as 4-Methylmethcathinone, M-CAT, Drone, Meow meow, among many others) is a synthetic entactogenic stimulant of the substituted cathinone class. It is known for producing a mixture of classic stimulant and entactogenic effects effects reminiscent of cocaine and MDMA.

It is chemically similar to the compounds that can be synthesized from cathinone as found in the khat (cathulla edullis) plant of eastern Africa.

It comes in the form of tablets or a powder, which users can swallow, snort, inject or insert rectally, producing effects which are somewhat similar to those of MDMA, amphetamine, and cocaine.

Mephedrone was first synthesized in 1929, but did not become widely known until it was rediscovered in 2003. By 2007, it was reported to be available for sale on the internet, by 2008 law enforcement agencies had become aware of the compound, and by 2010 it had been reported in most of Europe, becoming particularly prevalent in the United Kingdom.

Mephedrone, or 4-methylmethcathinone, is a synthetic molecule of the cathinone family. Cathinones are structurally similar to amphetamines, they contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. Amphetamines and cathinones are alpha-methylated phenethylamines, cathinones contain an additional carbonyl group at R1. Mephedrone contains an additional methyl substitutions at RN, similarly to MDMA and methamphetamine, and R4 of its phenyl ring.

Given its chemical structure, mephedrone is likely to act as a releasing agent and a reuptake inhibitor for monoamine neurotransmitters such as dopamine, serotonin and noradrenaline.

Several articles published near the end of 2011 examined the effects of mephedrone in the brains of rats, as well as examining the reinforcing potential of mephedrone. Dopamine and serotonin were collected using microdialysis, and increases in dopamine and serotonin were measured. Mephedrone administration caused about a 500% increase in dopamine, and about a 950% increase in serotonin. They reached their peak concentrations at 40 minutes and 20 minutes and returned to baseline by 120 minutes after injection.

Analysis of the ratio for dopamine and serotonin indicated mephedrone was preferentially a serotonin releaser, with a ratio of 1.22:1 (serotonin vs. dopamine). Additionally, half-lives for the decrease in dopamine and serotonin were calculated and found to have decay rates of 24.5 minutes and 25.5 minutes.